INTRODUCTION: Cystic fibrosis transmembrane conductance regulator modulator therapy improves nutritional status and quality of life. Clinical trials have shown pancreatic insufficiency conversion, mostly in pediatric patients treated with ivacaftor. Studies with elexacaftor/tezacaftor/ivacaftor (ETI) in older patients have not suggested restoration of exocrine pancreas function, but quality data in adults are lacking. Our aim was to show the effect of ETI in adults with cystic fibrosis (CF) on nutritional status and digestive function. We hypothesized improvement of nutritional parameters and gastrointestinal symptoms, reduction of pancreatic enzyme replacement therapy, but uncertain improvement in exocrine pancreatic function. METHODS: We prospectively enrolled adults with CF treated with ETI from August 2021 to June 2022. We measured anthropometric parameters, laboratory nutritional markers, change of fecal elastase, pancreatic enzymes replacement therapy needs, and gastrointestinal symptoms. RESULTS: In the cohort of 29 patients (mean age 29.1 years), 82.8% suffered exocrine pancreatic insufficiency. After ETI, mean BMI increased by 1.20 kg/m2 (p < 0.001), mean body weight by 3.51 kg (p < 0.001), albumin by 2.81 g/L, and prealbumin by 0.06 (both p < 0.001). Only 1 patient, initially pancreatic insufficient (4.5%, p < 0.001), developed pancreatic sufficiency, indicated by increased fecal elastase from 45 μg/g to 442.1 μg/g. Mean change in lipase substitution decreased by 1,969 units/kg/day (p < 0.001) and stools frequency by 1.18 per day (p < 0.001). CONCLUSION: Our data suggest increased nutritional parameters, lower pancreatic substitution requirements, and improved defecation in adult CF patients on ETI. Improvement in exocrine pancreatic function might be mutation-specific and needs further study.

2nd Department of Internal Medicine Gastroenterology and Geriatrics University Hospital Olomouc Olomouc Czechia

Department of Children's Infectious Diseases University Hospital Brno Brno Czechia

Department of Gastroenterology and Digestive Endoscopy Masaryk Memorial Cancer Institute Brno Czechia

Department of Pneumology 2nd Faculty of Medicine Charles University and Motol University Hospital Prague Czechia

Department of Respiratory Diseases University Hospital Brno Brno Czechia

Department of Surgery University Hospital Brno Brno Czechia

Faculty of Medicine and Dentistry Palacky University Olomouc Olomouc Czechia

Faculty of Medicine Masaryk University Brno Czechia

Institute of Biostatistics and Analyses s r o Brno Czechia

Zobrazit více v PubMed

Shteinberg M, Haq IJ, Polineni D, Davies JC. Cystic fibrosis. Lancet. 2021;397(10290):2195–211. PubMed

Phillips ME, Hopper AD, Leeds JS, Roberts KJ, McGeeney L, Duggan SN, et al. . Consensus for the management of pancreatic exocrine insufficiency: UK practical guidelines. BMJ Open Gastroenterol. 2021;8(1):e0000643. PubMed PMC

Singh VK, Schwarzenberg SJ. Pancreatic insufficiency in cystic Fibrosis. J Cyst Fibros. 2017;16(Suppl 2):S70–8. PubMed

Löhr JM, Dominguez-Munoz E, Rosendahl J, Besselink M, Mayerle J, Lerch MM, et al. . United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis (HaPanEU). United Eur Gastroenterol J. 2017;5(2):153–99. PubMed PMC

Bass R, Brownell JN, Stallings VA. The impact of highly effective CFTR modulators on growth and nutrition status. Nutrients. 2021;13(9):2907. PubMed PMC

Middleton PG, Mall MA, Drevinek P, Lands LC, McKone EF, Polineni D, et al. . Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele. N Eng J Med. 2019;381(19):1809–19. PubMed PMC

Griese M, Costa S, Linnemann RW, Mall MA, McKone EF, Polineni D, et al. . Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial. Am J Resp Crit Care Med. 2021;203(3):381–5. PubMed PMC

Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, et al. . Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019;394(10212):1940–8. PubMed PMC

Carnovale V, Iacotucci P, Terlizzi V, Colangelo C, Ferrillo L, Pepe A, et al. . Elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis homozygous for the F508del mutation and advanced lung disease: a 48-week observational study. J Clin Med. 2022;11(4):1021. PubMed PMC

Petersen MC, Begnel L, Wallendorf M, Litvin M. Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis. J Cyst Fibros. 2022;21(2):265–71. PubMed PMC

Ramsey ML, Li SS, Fara LF, Gokun Y, Akshintala VS, Conwell DL, et al. . Cystic fibrosis transmembrane conductance regulator modulators and the exocrine pankreas: a scoping review. J Cyst Fibros. 2023;22(2):193–200. PubMed

Nichols AL, Davies JC, Jones D, Carr SB. Restoration of exocrine pancreatic function in older children with cystic fibrosis on ivacaftor. Paediatr Respir Rev. 2020;35(35):99–102. PubMed

Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Drevinek P, et al. . A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365(18):1663–72. PubMed PMC

Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, et al. . Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Eng J Med. 2015;373(3):220–31. PubMed PMC

Taylor-Cousar JL, Munck A, McKone EF, van der Ent CK, Moeller A, Simard C, et al. . Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del. N Eng J Med. 2017;377(21):2013–23. PubMed

Rosenfeld M, Cunningham S, Harris WT, Lapey A, Regelmann WE, Sawicki S, et al. . An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5 years (KLIMB). J Cyst Fibros. 2019;18(6):838–43. PubMed PMC

Rosenfeld M, Wainwright CE, Higgins M, Wang LT, Mckee C, Campbell D, et al. . Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study. Lancet Resp Med. 2018;6(7):545–53. PubMed PMC

Davies JC, Cunningham S, Harris WT, Lapey A, Regelmann WE, Sawicki GS, et al. . Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study. Lancet Respir Med. 2016;4(2):107–15. PubMed PMC

Stallings VA, Sainath N, Oberle M, Bertolaso C, Schall JI. Energy balance and mechanisms of weight gain with ivacaftor treatment of cystic fibrosis gating mutations. J Pediatr. 2018;201:229–37.e4. PubMed

Kounis I, Lévy P, Rebours V. Ivacaftor CFTR potentiator therapy is efficient for pancreatic manifestations in cystic fibrosis. Am J Gastroenterol. 2018;113(7):1058–9. PubMed

Crowley J, Croinin K, Mullane D, Chróinín MN. Restoration of exocrine pancreatic function in child with lumacaftor/ivacaftor therapy in cystic fibrosis. J Cyst Fibros. 2022;21(2):264. PubMed

Wright BA, Cannon ME, Ramsey LJ. Reversing the irreversible: another potential benefit of CFTR modulators. Pediatr Pulmonol. 2020;55(11):2844–5. PubMed

Terlizzi V, Amato F, Castellani C, Ferrari B, Galietta LJV, Castaldo G, et al. . Ex vivo model predicted in vivo efficacy of CFTR modulator therapy in a child with rare genotype. Mol Genet Genomic Med. 2021;9(4):e1656. PubMed PMC

McNamara JJ, McColley SA, Marigowda G, Liu F, Tian S, Owen CA, et al. . Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study. Lancet Respir Med. 2019;7(4):325–35. PubMed

Gould MJ, Smith H, Rayment JH, Machida H, Gonska T, Galante GJ. CFTR modulators increase risk of acute pancreatitis in pancreatic insufficient patients with cystic fibrosis. J Cyst Fibros. 2022;21(4):600–2. PubMed

Davies JC, Sermet-Gaudelus I, Naehrlich L, Harris RS, Campbell D, Ahluwalia N, et al. . A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation. J Cyst Fibros. 2021;20(1):68–77. PubMed

Schwarzenberg SJ, Vu PT, Skalland M, Hoffman LR, Pope C, Gelfond D, et al. . Elexacaftor/tezacaftor/ivacaftor and gastrointestinal outcomes in cystic fibrosis: report of promise-GI. J Cyst Fibros. 2023;22(2):282–9. PubMed PMC

Emery J, Mullane D, Chroinin MN. The effects of ivacaftor on pancreatic function in paediatric patients with cystic fibrosis gating mutations. Arch Dis Child. 2019;104:A149–50.

Gomez-Pastrana D, Nwokoro C, McLean M, Brown S, Christiansen N, Pao CS. Real-world effectiveness of ivacaftor in children with cystic fibrosis and the G551D mutation. An Pediatr. 2019;90(3):148–56. PubMed

Sergeev V, Chou FY, Lam GY, Hamilton CM, Wilcox PG, Quon BS. The extrapulmonary effects of cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis. Ann Am Thorac Soc. 2020;17(2):147–54. PubMed PMC

Freeman AJ. The impact of modulator therapies on pancreatic exocrine function: the good, the bad and the potentially ugly. J Cyst Fibros. 2022;21(4):560–1. PubMed

Gelfond D, Heltshe S, Ma C, Rowe SM, Frederick C, Uluer A, et al. . Impact of CFTR modulation on intestinal pH, motility and clinical outcomes in patients with cystic fibrosis and the G551D mutation. Clin Transl Gastroenterol. 2017;8(3):e81. PubMed PMC

Stastna N, Pokojova E. Case report of two adults with F508del/3849+10kb C>T genotype regaining exocrine pancreatic function following treatment with elexacaftor/tezacaftor/ivacaftor. J Cyst Fibros. 2023. PubMed

Clinical and Functional Translation of CFTR (CFTR2) . US CF foundation. Johnd Hopkins University, The Hospital for Sick Children; 2021. [cited 2022 Dec 11]. Available from: http://cftr2.org.